Subscribe
Shawn Konopaski / Shutterstock.com
17 December 2025NewsAmericasLiz Hockley

SCOTUS shuts the door on Entresto ‘after-arising technology’ review

The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the pharmaceutical industry, but for all stakeholders in our patent system”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis moves to quash SCOTUS review of Entresto case
13 November 2025   Pharma company tells court generics rival’s petition is “not the subject of any legal conflict”, as it reassures investors that a $12bn biotech acquisition will deliver growth.


Editor's picks

Abbott appeals ‘baffling’ decision in glucose monitoring device feud
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025

Editor's picks

Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

More features

Morgan Lewis continues coast-to-coast US expansion with life sciences specialist
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
Beyond traditional IP: A comprehensive AI strategy for life sciences
Winston & Strawn and Taylor Wessing UK plan transatlantic combo
Diagnosis: What’s holding back UK life sciences?
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
Arnold & Porter grows life sciences transactions bench with London hire
Prosecuting bispecific antibody patents: A cookbook for patent chefs